Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 3Recruiting 3Not yet recruiting 3Unknown 2Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 44Breast Neoplasms 41Triple Negative Breast Neoplasms 34Ovarian Neoplasms 28Small Cell Lung Carcinoma 26Squamous Cell Carcinoma of Head and Neck 23Fallopian Tube Neoplasms 18Endometrial Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 13Uterine Cervical Neoplasms 12Esophageal Squamous Cell Carcinoma 12Prostatic Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 10Esophageal Neoplasms 10Colorectal Neoplasms 9Recurrence 8Carcinoma, Transitional Cell 8Oropharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Neuroblastoma 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma, Large B-Cell, Diffuse 5Lung Diseases 5Adenocarcinoma of Lung 5Thoracic Neoplasms 4

Interventions

Drug Therapy 4Pemetrexed 3Carboplatin 3osimertinib 2Radiotherapy 2toripalimab 1tislelizumab 1sugemalimab 1spartalizumab 1sintilimab 1pembrolizumab 1cemiplimab 1aflutinib 1Vinorelbine 1Radiosurgery 1Platinum 1Paclitaxel 1Gemcitabine 1Docetaxel 1Cisplatin 1Chemotherapy, Adjuvant 1Anterior Temporal Lobectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × NSCLC × Carboplatin × Clear all
NCT07082179 2026-02-11

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

Jiangsu Cancer Institute & Hospital

Phase 2 Recruiting
33 enrolled
Thoracic

NSCLC

NCT07181499 2025-09-30

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Betta Pharmaceuticals Co., Ltd.

Phase 2 Recruiting
28 enrolled
Thoracic

NSCLC

NCT06754644 2025-06-10

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
808 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡